This current report builds on previous analyses [3,4,5] and extends the age groups included. An overview of outcomes, study period and age groups included in the analysis are presented in Table 1 Previous ECDC publications on COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2, are available [3,4]. This third update contains vaccine effectiveness results among individuals aged 20 years and older for the Omicron period) for the first time as well as estimates by COVID-19 vaccine product (i.e. Comirnaty and Vaxzevria).